These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 30382889

  • 21. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer.
    Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, Emmett L.
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.
    Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, Hofman MS, Eiber M, Schwarzenbock S, Castellucci P, Bellisario C, Chauvie S, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A.
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1622-1635. PubMed ID: 28536833
    [Abstract] [Full Text] [Related]

  • 25. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [Abstract] [Full Text] [Related]

  • 26. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 27. 68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.
    Iravani A, Hofman MS, Mulcahy T, Williams S, Murphy D, Parameswaran BK, Hicks RJ.
    Cancer Imaging; 2017 Dec 21; 17(1):31. PubMed ID: 29268784
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
    Sahlmann CO, Meller B, Bouter C, Ritter CO, Ströbel P, Lotz J, Trojan L, Meller J, Hijazi S.
    Eur J Nucl Med Mol Imaging; 2016 May 21; 43(5):898-905. PubMed ID: 26563122
    [Abstract] [Full Text] [Related]

  • 31. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
    Afaq A, Bomanji J.
    Br Med Bull; 2018 Dec 01; 128(1):37-48. PubMed ID: 30272121
    [Abstract] [Full Text] [Related]

  • 32. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
    Verma P, Malhotra G, Agrawal R, Sonavane S, Meshram V, Asopa RV.
    Clin Nucl Med; 2018 Aug 01; 43(8):e265-e268. PubMed ID: 29894335
    [Abstract] [Full Text] [Related]

  • 33. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
    Domachevsky L, Bernstine H, Goldberg N, Nidam M, Catalano OA, Groshar D.
    Eur Radiol; 2020 Jan 01; 30(1):328-336. PubMed ID: 31332559
    [Abstract] [Full Text] [Related]

  • 34. Bone Flare to Androgen Deprivation Therapy in Metastatic, Hormone-Sensitive Prostate Cancer on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
    Zacho HD, Petersen LJ.
    Clin Nucl Med; 2018 Nov 01; 43(11):e404-e406. PubMed ID: 30222680
    [Abstract] [Full Text] [Related]

  • 35. Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse.
    Regula N, Kostaras V, Johansson S, Trampal C, Lindström E, Lubberink M, Velikyan I, Sörensen J.
    Sci Rep; 2020 Mar 19; 10(1):4993. PubMed ID: 32193430
    [Abstract] [Full Text] [Related]

  • 36. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
    Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A.
    Nucl Med Commun; 2017 Nov 19; 38(11):956-963. PubMed ID: 28922335
    [Abstract] [Full Text] [Related]

  • 37. The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy.
    Al-Ibraheem A, Abuhijla F, Salah S, Shahait M, Khader J, Mohamad I, Al-Rasheed U, Pomykala KL, Herrmann K, Abu-Hijlih R.
    Nucl Med Commun; 2021 Jul 01; 42(7):811-817. PubMed ID: 33660693
    [Abstract] [Full Text] [Related]

  • 38. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG.
    Eur Urol; 2020 Apr 01; 77(4):403-417. PubMed ID: 30773328
    [Abstract] [Full Text] [Related]

  • 39. A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.
    Pernthaler B, Kulnik R, Gstettner C, Salamon S, Aigner RM, Kvaternik H.
    Clin Nucl Med; 2019 Oct 01; 44(10):e566-e573. PubMed ID: 31283605
    [Abstract] [Full Text] [Related]

  • 40. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 May 01; 44(5):765-775. PubMed ID: 27900519
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.